4 years ago

MiNA Therapeutics Secures $15 Million from Eli Lilly for RNA Therapeutics

  • MiNA Therapeutics, a London-based provider of small activating RNA therapeutics, has received a $15 million equity investment from Eli Lilly and Company

  • The company plans to use the funds to advance and expand its internal pipeline of saRNA therapeutics, which focuses on immuno-oncology and genetic diseases

  • MiNA Therapeutics is leading the development of small activating RNA therapeutics, a new class of medicines that can restore or boost normal function in patients' cells.

      • ProblemHealthcare

      "making available medicine options to treat genetic diseases and cancer"

      Solution

      "developing small activating RNA therapeutics that can restore or boost normal function in patients' cells"

      Covered on